{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:06:35Z","timestamp":1781010395550,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40123-026-01375-4","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:45:13Z","timestamp":1776339913000},"page":"1869-1877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dry Eye Disease: Perspectives of a Patient and Both US and UK Physicians"],"prefix":"10.1007","volume":"15","author":[{"given":"Irene S.","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiresh","family":"Bandaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacklyn","family":"Vainshtein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Rampat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagny","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"1375_CR1","unstructured":"Treating Evaporative Dry Eye Associated with Meibomian Gland Dysfunction. American Academy of Ophthalmology. September 1, 2019. https:\/\/www.aao.org\/eyenet\/article\/treating-evaporative-dry-eye. Accessed 23 Sept 2025."},{"issue":"5","key":"1375_CR2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/ICO.0b013e318225415a","volume":"31","author":"MA Lemp","year":"2012","unstructured":"Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472\u20138. https:\/\/doi.org\/10.1097\/ICO.0b013e318225415a.","journal-title":"Cornea"},{"issue":"3","key":"1375_CR3","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s40123-023-00669-1","volume":"12","author":"JD Sheppard","year":"2023","unstructured":"Sheppard JD, Nichols KK. Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape. Ophthalmol Ther. 2023;12(3):1397\u2013418. https:\/\/doi.org\/10.1007\/s40123-023-00669-1.","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"1375_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276\u201383. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.008.","journal-title":"Ocul Surf"},{"key":"1375_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.107724","volume":"186","author":"C Portal","year":"2019","unstructured":"Portal C, Gouyer V, Gottrand F, Desseyn JL. Ocular mucins in dry eye disease. Exp Eye Res. 2019;186:107724. https:\/\/doi.org\/10.1016\/j.exer.2019.107724.","journal-title":"Exp Eye Res"},{"issue":"3","key":"1375_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/bjophthalmol-2015-307415","volume":"100","author":"C Baudouin","year":"2016","unstructured":"Baudouin C, Messmer EM, Aragona P, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100(3):300\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307415.","journal-title":"Br J Ophthalmol"},{"issue":"14","key":"1375_CR7","doi-asserted-by":"publisher","first-page":"ORSF1","DOI":"10.1167\/iovs.13-12993","volume":"54","author":"GJ Chader","year":"2013","unstructured":"Chader GJ, Taylor A. Preface: the aging eye: normal changes, age-related diseases, and sight-saving approaches. Investig Ophthalmol Vis Sci. 2013;54(14):ORSF1\u20134. https:\/\/doi.org\/10.1167\/iovs.13-12993.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"3","key":"1375_CR8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334\u201365. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.003.","journal-title":"Ocul Surf"},{"issue":"4","key":"1375_CR9","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1167\/iovs.10-6997e","volume":"52","author":"DA Schaumberg","year":"2011","unstructured":"Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Investig Ophthalmol Vis Sci. 2011;52(4):1994\u20132005. https:\/\/doi.org\/10.1167\/iovs.10-6997e.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"3","key":"1375_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2023.101837","volume":"46","author":"M Vidal-Rohr","year":"2023","unstructured":"Vidal-Rohr M, Craig JP, Davies LN, Wolffsohn JS. The epidemiology of dry eye disease in the UK: the Aston dry eye study. Contact Lens Anterior Eye. 2023;46(3):101837. https:\/\/doi.org\/10.1016\/j.clae.2023.101837.","journal-title":"Contact Lens Anterior Eye"},{"issue":"3","key":"1375_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/02713683.2020.1801758","volume":"46","author":"M Borrelli","year":"2021","unstructured":"Borrelli M, Frings A, Geerling G, Finis D. Gender-specific differences in signs and symptoms of dry eye disease. Curr Eye Res. 2021;46(3):294\u2013301. https:\/\/doi.org\/10.1080\/02713683.2020.1801758.","journal-title":"Curr Eye Res"},{"issue":"4","key":"1375_CR12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802\u201312. https:\/\/doi.org\/10.1016\/j.jtos.2017.08.003.","journal-title":"Ocul Surf"},{"key":"1375_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ajo.2025.05.039","volume":"279","author":"L Jones","year":"2025","unstructured":"Jones L, Craig JP, Markoulli M, et al. TFOS DEWS III: management and therapy. Am J Ophthalmol. 2025;279:289\u2013386. https:\/\/doi.org\/10.1016\/j.ajo.2025.05.039.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1375_CR14","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1167\/iovs.10-6997g","volume":"52","author":"G Geerling","year":"2011","unstructured":"Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Investig Ophthalmol Vis Sci. 2011;52(4):2050\u201364. https:\/\/doi.org\/10.1167\/iovs.10-6997g.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"15","key":"1375_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare12151487","volume":"12","author":"PG Davey","year":"2024","unstructured":"Davey PG, Farid M, Karpecki P, et al. Lotilaner ophthalmic solution, 0.25%, for the treatment of Demodex blepharitis. Healthcare. 2024;12(15):1487. https:\/\/doi.org\/10.3390\/healthcare12151487.","journal-title":"Healthcare"},{"issue":"9","key":"1375_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1097\/ICO.0000000000002622","volume":"40","author":"J Tauber","year":"2021","unstructured":"Tauber J, Wirta DL, Sall K, et al. A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease. Cornea. 2021;40(9):1132\u201340. https:\/\/doi.org\/10.1097\/ICO.0000000000002622.","journal-title":"Cornea"},{"issue":"12","key":"1375_CR17","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1097\/ICO.0b013e31823cc098","volume":"31","author":"P Prabhasawat","year":"2012","unstructured":"Prabhasawat P, Tesavibul N, Mahawong W. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea. 2012;31(12):1386\u201393. https:\/\/doi.org\/10.1097\/ICO.0b013e31823cc098.","journal-title":"Cornea"},{"issue":"1","key":"1375_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","volume":"124","author":"EJ Holland","year":"2017","unstructured":"Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124(1):53\u201360. https:\/\/doi.org\/10.1016\/j.ophtha.2016.09.025.","journal-title":"Ophthalmology"},{"key":"1375_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ajo.2017.08.021","volume":"183","author":"R Liu","year":"2017","unstructured":"Liu R, Rong B, Tu P, et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. Am J Ophthalmol. 2017;183:81\u201390. https:\/\/doi.org\/10.1016\/j.ajo.2017.08.021.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1375_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/ICL.0000000000000166","volume":"42","author":"JV Greiner","year":"2016","unstructured":"Greiner JV. Long-term (3 year) effects of a single thermal pulsation system treatment on meibomian gland function and dry eye symptoms. Eye Contact Lens. 2016;42(2):99\u2013107. https:\/\/doi.org\/10.1097\/ICL.0000000000000166.","journal-title":"Eye Contact Lens"},{"issue":"7","key":"1375_CR21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/ICO.0b013e3181cda38f","volume":"29","author":"GN Foulks","year":"2010","unstructured":"Foulks GN, Borchman D, Yappert M, Kim SH, McKay JW. Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. Cornea. 2010;29(7):781\u20138. https:\/\/doi.org\/10.1097\/ICO.0b013e3181cda38f.","journal-title":"Cornea"},{"issue":"1","key":"1375_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/ICO.0b013e318254205f","volume":"32","author":"GN Foulks","year":"2013","unstructured":"Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea. 2013;32(1):44\u201353. https:\/\/doi.org\/10.1097\/ICO.0b013e318254205f.","journal-title":"Cornea"},{"issue":"10","key":"1375_CR23","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1097\/ICO.0b013e3181d836f3","volume":"29","author":"SL Maskin","year":"2010","unstructured":"Maskin SL. Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction. Cornea. 2010;29(10):1145\u201352. https:\/\/doi.org\/10.1097\/ICO.0b013e3181d836f3.","journal-title":"Cornea"},{"key":"1375_CR24","unstructured":"Oculis. A multi-center, randomized, double-masked, vehicle-controlled study evaluating the efficacy and safety of licaminlimab for the treatment of dry eye disease. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT05896670. Accessed 23 Sept 2025."},{"issue":"1","key":"1375_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100938","volume":"6","author":"S Garg","year":"2025","unstructured":"Garg S, Donnenfeld E, Sheppard J, Epitropoulos A, Brady TC. Reproxalap improves ocular redness, tear production, and symptoms in a pivotal dry eye disease chamber trial. Ophthalmol Sci. 2025;6(1):100938. https:\/\/doi.org\/10.1016\/j.xops.2025.100938.","journal-title":"Ophthalmol Sci"},{"key":"1375_CR26","unstructured":"Azura Ophthalmics. A phase 3, multicenter, vehicle-controlled, randomized study to evaluate the efficacy, safety, and tolerability of AZR-MD-001 in patients with abnormal meibomian gland function and associated symptoms of dry eye disease (DED). clinicaltrials.gov; 2024. https:\/\/clinicaltrials.gov\/study\/NCT06329791. Accessed 23 Sept 2025."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01375-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01375-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01375-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:27:27Z","timestamp":1781008047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01375-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1375"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01375-4","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Irene Zhou has nothing to disclose. Dhiresh Bandaru has nothing to disclose. Jacklyn Vainshtein has nothing to disclose. Radhika Rampat is a consultant for Tarsus Pharmaceuticals. Dagny Zhu is a consultant for Abbvie and Bausch\u2009+\u2009Lomb. The patient author Emily Clark is a full-time employee of Springer Nature. Emily had no involvement in the peer review, or editorial decisions, or processing of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was HIPAA compliant, did not require IRB approval and was in accordance with the Declaration of Helsinki. Consent for participation and publication was obtained from all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}